Aquestive officer may sell 8,750 shares

Officer Sherry M. Korczynski filed a Rule 144 notice to potentially sell 8,750 AQST common shares from option exercises on September 9, 2026.

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. (AQST) is the issuer for a planned resale of its common stock reported under Rule 144 by officer Sherry M. Korczynski. The notice covers up to 8,750 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, arising from an exercise of stock options for cash, with an approximate aggregate market value of $45,587.50, and a stated sale date of September 9, 2026 on NASDAQ.

Key Figures

Shares of common stock covered: 8,750 shares Approximate aggregate market value: $45,587.50 Planned sale date: September 9, 2026 +1 more

4 metrics

Shares of common stock covered 8,750 shares Maximum number of Aquestive Therapeutics common shares indicated for sale under Rule 144

Approximate aggregate market value $45,587.50 Value associated with the 8,750 shares of common stock in the Form 144

Planned sale date September 9, 2026 Date listed for the sale of common stock and the option exercise

Shares from option exercise 8,750 shares Common shares to be acquired via exercise of stock options for cash

Key Terms

Rule 144, Exercise of Stock Options, Issuer

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Common | 09/09/2026 | Exercise of Stock Options | Issuer"

Issuer financial

"Exercise of Stock Options | Issuer | | | 8750"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Aquestive Therapeutics (AQST)?

The Form 144 reports that an officer, Sherry M. Korczynski, may sell up to 8,750 shares of Aquestive Therapeutics common stock under Rule 144, following an exercise of stock options for cash, with sales indicated for September 9, 2026 on NASDAQ.

How many AQST shares are covered by Sherry M. Korczynski’s Form 144?

The notice covers up to 8,750 shares of Aquestive Therapeutics common stock. These shares are tied to an exercise of stock options and may be sold through Morgan Stanley Smith Barney LLC as the broker.

What is the approximate value of the AQST shares in this Form 144 notice?

The Form 144 lists an approximate aggregate market value of $45,587.50 for the 8,750 shares of Aquestive Therapeutics common stock that may be sold by officer Sherry M. Korczynski.

When are the AQST shares in this Form 144 planned to be sold?

The Form 144 indicates a planned sale date of September 9, 2026 for the 8,750 shares of Aquestive Therapeutics common stock related to the exercise of stock options.

How will the AQST shares in this Form 144 be acquired before sale?

The Form 144 specifies that the 8,750 shares of Aquestive Therapeutics common stock will come from an exercise of stock options on September 9, 2026, with the exercise to be paid in cash.

Which broker is handling the potential AQST share sale under this Form 144?

The notice lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the potential sale of 8,750 shares of Aquestive Therapeutics common stock on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:21 PM EDT Accepted by SEC EDGAR 09/09/2026 - 04:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002026090
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Aquestive Therapeutics, Inc.
SEC File Number	001-38599
Address of Issuer	30 Technology Drive Warren NEW JERSEY 07059
Phone	9089411900
Name of Person for Whose Account the Securities are To Be Sold	Sherry M. Korczynski
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8750	45587.50	125511648	09/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/09/2026	Exercise of Stock Options	Issuer			8750	09/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Sherry M. Korczynski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)